

**Form 51-102F3**  
***Material Change Report***

**1. Name and Address of Company**

**Entheon Biomedical Corp.**  
Suite 720 - 999 W Broadway Street  
Vancouver, BC  
V5Z 1K5  
(the "Company")

**2. Dates of Material Change(s)**

March 14, 2025

**3. News Release(s)**

News release was issued on March 14, 2025 and disseminated via Newsfile pursuant to section 7.1 of National Instrument 51-102.

**4. Summaries of Material Changes**

The Company announces that, further to its news release dated January 24, 2025, 1000141080 Ontario Ltd. ("Mentis AI") has terminated the letter of intent ("LOI") dated January 23, 2025 which set out the terms whereby Entheon would acquire all of the issued and outstanding common shares in the capital of Mentis AI.

**5. Full Description of Material Changes**

News Release dated March 14, 2025— See Schedule "A".

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**7. Omitted Information**

No information has been omitted.

**8. Executive Officer**

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

**9. Date of Report**

This report is dated March 17, 2025

SCHEDULE "A"  
to the Material Change Report dated March 17, 2025

**Entheon Announces Termination of Mentis AI Agreement**

**VANCOUVER, BC, March 14, 2025** – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("**Entheon**" or the "**Company**") announces that, further to its news release dated January 24, 2025, 1000141080 Ontario Ltd. ("**Mentis AI**") has terminated the letter of intent ("**LOI**") dated January 23, 2025 which set out the terms whereby Entheon would acquire all of the issued and outstanding common shares in the capital of Mentis AI.

**About Entheon Biomedical Corp.**

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

**On Behalf of the Board of Directors,**  
Timothy Ko, CEO, President and Director

For more information, please contact the Company at:  
Entheon Biomedical Corp.  
Timothy Ko, CEO  
1 (604) 562-3932  
timothy@entheonbiomedical.com  
<https://entheonbiomedical.com>